Flow cytometry is the laboratory test that tells us which kind of leukemia a patient has, and later, whether any leukemia cells remain after treatment. It works by reading the proteins on the surface and inside of thousands of individual cells per second, so a sample of blood or bone marrow can be sorted into normal cells and abnormal ones within hours. In short, its role in leukemia is to confirm the diagnosis, classify the subtype, and track response to therapy.
Flow cytometry sits at the heart of modern hematology. Below, I explain how the test works, what it can and cannot tell you, and how its results shape treatment decisions.
How Flow Cytometry Works
A flow cytometer pushes cells in single file through a narrow stream of fluid, past one or more lasers. As each cell crosses the beam, detectors measure how the light scatters and how brightly the cell glows.
Before the sample goes in, the lab mixes it with fluorescently labeled antibodies. Each antibody sticks to one specific protein, called a CD marker (cluster of differentiation), and carries a dye of a particular color. By combining many colors in one tube, the machine builds a profile of every cell it sees.
What the machine measures
- Forward scatter roughly reflects cell size.
- Side scatter reflects internal complexity, such as granules in neutrophils.
- Fluorescence shows which CD markers a cell carries and how strongly.
Put together, these readings produce an immunophenotype: a fingerprint of the cell’s lineage and maturity. Healthy white blood cells follow predictable patterns as they mature. Leukemia cells usually break those patterns, and that deviation is what the hematopathologist looks for.
Flow Cytometry in Diagnosing Leukemia
Most leukemia workups start with a complete blood count (CBC) and a blood smear. If the smear shows blasts (immature cells) or an unusual population of lymphocytes, flow cytometry is typically the next step, often on peripheral blood and then on a sample from the bone marrow.
The first question flow cytometry answers is lineage. Is this a myeloid leukemia, a B-cell leukemia, or a T-cell leukemia? That distinction drives almost every decision that follows.
Common marker patterns
The table below shows typical, simplified marker patterns. Real panels use many more markers, and individual cases vary.
| Leukemia type | Typical markers | What it suggests |
|---|---|---|
| Acute myeloid leukemia (AML) | CD34, CD117, CD13, CD33, MPO | Immature myeloid blasts |
| B-cell acute lymphoblastic leukemia (B-ALL) | CD19, CD10, CD22, TdT, CD34 | Immature B-cell blasts |
| T-cell acute lymphoblastic leukemia (T-ALL) | Cytoplasmic CD3, CD7, TdT | Immature T-cell blasts |
| Chronic lymphocytic leukemia (CLL) | CD5, CD19, CD23, dim CD20, dim light chain | Mature, clonal B cells |
| Hairy cell leukemia | CD11c, CD25, CD103, CD123 | Distinct mature B-cell disorder |
Proving a population is clonal
For mature B-cell disorders such as CLL, flow cytometry can show light-chain restriction. Normal B cells carry a mix of kappa and lambda light chains. When nearly all of them carry only one type, that points to a single abnormal clone rather than a reaction to infection.
What Flow Cytometry Cannot Tell You
Flow cytometry is powerful, but it is one piece of a larger diagnostic picture. It describes proteins on cells; it does not read the genes inside them.
- Cytogenetics (karyotype and FISH) finds chromosomal changes such as the Philadelphia chromosome, which creates the BCR-ABL1 fusion in chronic myeloid leukemia.
- Molecular testing detects mutations such as NPM1 or FLT3 in AML, which strongly affect prognosis.
- Morphology, looking at cells under the microscope, remains essential for counting blasts and spotting features like Auer rods.
Modern classification systems combine all of these. In my experience, the best diagnoses come when the flow report, the marrow slides, and the genetic results are read side by side rather than in isolation.
Flow Cytometry in Managing Leukemia
Once treatment begins, flow cytometry changes roles. It stops asking “what is this?” and starts asking “is any of it left?”
Measurable residual disease (MRD)
Measurable residual disease, also called minimal residual disease, refers to leukemia cells that remain after treatment but are too few to see under a microscope. A marrow can look normal on a slide and still contain a small number of leukemic cells.
Because leukemia cells often carry an unusual combination of markers, a sensitive flow panel can pick out a very small number of them among many normal cells. This is especially well established in acute lymphoblastic leukemia, where MRD status after induction therapy is one of the strongest predictors of outcome and is used to adjust how intensive further treatment should be.
Guiding targeted therapy
Many newer treatments aim at a specific surface marker. Flow cytometry confirms that the target is actually present before treatment and can show whether it is lost afterward.
| Target marker | Example treatment approach | Why flow matters |
|---|---|---|
| CD19 | CAR T-cell therapy, bispecific antibodies | Confirms target before therapy; detects CD19-negative relapse |
| CD22 | Antibody-drug conjugates | Shows how strongly blasts express the target |
| CD33 | Antibody-drug conjugates in AML | Confirms expression on myeloid blasts |
| CD20 | Anti-CD20 antibodies in CLL | Confirms the target on clonal B cells |
For a broader look at therapy options, see our overview of leukemia treatment strategies.
What to Expect as a Patient
From the patient’s side, flow cytometry does not require a separate procedure. The lab uses a tube of blood or part of the bone marrow aspirate collected for other tests.
- Sample collection: a routine blood draw, or a bone marrow aspirate from the back of the hip bone.
- Processing: the lab stains the cells with antibody panels, usually on the same day because cells degrade quickly.
- Interpretation: a hematopathologist reviews the plots and writes a report describing any abnormal population.
- Follow-up testing: repeat samples during and after treatment check for MRD.
Results for a new suspected acute leukemia are often available within a day or two, which matters because some acute leukemias need treatment urgently.
Key Takeaways
- Flow cytometry identifies leukemia cells by the proteins they carry, producing an immunophenotype.
- It quickly separates myeloid from lymphoid and B-cell from T-cell leukemias.
- It works alongside morphology, cytogenetics, and molecular testing, not instead of them.
- During treatment, it measures residual disease and confirms targets for antibody and cellular therapies.
- If you have unexplained fatigue, fevers, frequent infections, or easy bruising, ask your doctor about a CBC; flow cytometry follows if the results are abnormal.
Frequently Asked Questions
Can flow cytometry diagnose leukemia from a blood test alone?
Sometimes. When many leukemia cells circulate in the blood, as in CLL or many acute leukemias, flow cytometry on peripheral blood can establish the diagnosis. A bone marrow biopsy is still usually done for acute leukemia to assess the marrow and provide material for genetic testing.
Is flow cytometry the same as genetic testing?
No. Flow cytometry measures proteins on and inside cells, while cytogenetic and molecular tests look at chromosomes and DNA. Both are needed, because genetic findings often determine risk group and specific drug choices.
What does an “MRD-negative” result mean?
It means the test did not detect leukemia cells at the level of sensitivity it can reach. It is generally a favorable sign, but it does not guarantee the leukemia is gone, so your team will continue monitoring.
How often will I need flow cytometry during treatment?
It depends on the type of leukemia and the treatment protocol. MRD is commonly checked at set points, such as after induction and after consolidation, and your hematologist will explain the schedule for your case.
